• There has been a significant increase in the number of opioid prescriptions filled and, consequently, a growing incidence of morbidity and mortality.
• Prescription drug misuse is a major public health concern and has significant costs associated with it.
• Safe oversight of pain management is difficult due to the inherent subjectivity of diagnosis and monitoring. Additionally, the opiate medication class has shown a dramatic increase in utilization due to misuse and abuse. These factors have resulted in increased emergency department visits and deaths from accidental overdoses.
• Methods to implement evidence-based guidelines and provide safe practices have not been thoroughly researched. The health care system in the United States is challenged with developing management strategies that balance best practice models, appropriate utilization, and reduction of costs associated with the opioid medication class.
In Massachusetts, treatment admissions for the abuse of opioids increased nearly 9-fold between 1992 and 2002. 23 In 2005, opioid analgesics ranked eighth in the top 10 drug classes utilized by the Massachusetts Medicaid Pharmacy program. 24 Furthermore, according to the 2006 NSDUH, Massachusetts ranked ninth nationally in the misuse of prescription pain relievers by those aged 18 and older. 25 Published data regarding oversight of opioid medications by state Medicaid pharmacy programs are limited. Effective utilization management strategies for Medicaid programs include the use of a preferred drug list and a prior authorization (PA) process. [26] [27] [28] [29] [30] A 2008 study summarizing the impact of 21 state Medicaid PA processes on oxycodone controlled-release demonstrated that changes in use and expenditures associated with PA implementation varied among states. However, a significant impact was not observed for most states. The authors concluded that, compared with other drugs, oxycodone extended-release (ER) prescribing and dosing appeared relatively unaffected by Medicaid PA requirements. 31 In direct response to the need for improved oversight and management of this medication class, Massachusetts Medicaid (MassHealth), through the Drug Utilization Review (DUR) program, began reviewing opioid utilization data in October 2002. A multistep strategy via the PA process was established, incorporating clinical approval criteria addressing defined high dose, daily dose, and preferred therapeutic alternatives on long-acting opioid analgesics (LAOA). The multiple steps of this initiative were implemented with changes to the MassHealth Drug List. The list is a nontiered formulary that provides information regarding coverage status of medication. The management strategies also included the creation of a Therapeutic Class Management (TCM) multidisciplinary team. In this article, we describe the process, timeline, implementation strategies, utilization, and economic outcomes of this LAOA initiative implemented by the Massachusetts Medicaid program.
■■ Methods Study Design
This study involved a retrospective claims-based data analysis that examined the impact of newly introduced PA restrictions on the management of selected LAOAs. Utilization data for the LAOAs were reviewed and compared for 2 time periods: the year prior to implementation of the initiative (2002) and the year after initiative implementation (2005) . Quantitative measures analyzed included number of unique utilizers and claims, as well as average daily dose captured by the pharmacy claims processing program. Average daily doses for each individual member were calculated by identifying the number of tablets, days' supply, and the dose for every claim filled during the review period. Not all opioids have the same clinical potencies, which may create a problem when attempting to compare dose societies, and the pharmaceutical industry began advocating for increased opioid use in the treatment of pain. 7, 8 National prescription-tracking data show that more than 40% of opioid prescriptions are written by general or family practitioners, osteopaths, or internists. 8 Data from the U.S. Drug Enforcement Agency (DEA) and the Drug Abuse Warning Network (DAWN) indicate large increases in medical and nonmedical use of opioid analgesics. Retail reported use of oxycodone has increased 403% and fentanyl transdermal system 227% between 1997 and 2002, as reported by the Automation of Reports and Consolidated Orders System (Arcos). 9 The Office of National Drug Control Policy (ONDCP) reported that from 1997 to 2007, there was a 4-fold increase in the milligram-per-person use of prescription opioids of 402% from an average of 74 to 369 milligrams (mg). The American Pain Society recognizes there is no defined high dose for morphine; however, a panel consensus has recently agreed that a reasonable definition is > 200 milligrams per day (mg/day) or the equivalent. 6, 10 In addition, the number of opioid prescriptions dispensed by pharmacies from 2000 to 2009 increased by 48%.
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As newer expert guidelines have encouraged the treatment of pain, there has been a subsequent increase in usage of prescribed opiates. This has resulted in a growing concern for potential harm, particularly from abuse and misuse.
12,13 A review of utilization from 1997 to 2005 found that there was a positive correlation between prescribed opioid doses and the risk of overdose events.
14 From 2004 to 2008, there was more than a 2-fold increase in emergency department visits related to opioid abuse. 15, 16 Furthermore, the Center for Disease Control and Prevention has reported that in 2007, the number of deaths associated with opioid overdoses was more than that of heroin and cocaine combined. 17 According to the 2010 National Survey on Drug Use and Health (NSDUH), approximately 5.1 million persons of age 12 and older reported the nonmedical use of pain relievers in the month preceding the survey. 18 There is a considerable cost associated with opioid abuse. It is estimated that the U.S. government spends approximately $300 billion per year in costs related to all types of drug abuse. 19 An analysis of data prior to 2007 estimated that the U.S. societal cost of prescription opioid abuse was $55.7 billion in 2009 dollars with workplace costs accounting for 46%, health care costs 45%, and criminal justice costs 9%. 20 Insurance expenditures (medications, hospitalizations, and physician visits) were over 8 times higher in opioid abusers than in nonabusers. 21 In April 2011, the ONDCP declared that prescription drug abuse and misuse "is a major public health and safety crisis." 22 A joint action plan was put in place by the ONDCP, the U.S. Food and Drug Administration, and the DEA calling for initiatives that included the education of health care providers and patients and enhanced monitoring of opioid prescribing. 11 or change in dose between opioids. Therefore, in this study, all doses were converted to oral morphine equivalents (OMEQ).
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Participants
Participants included any MassHealth member enrolled in the Massachusetts Medicaid pharmacy benefit during any time period between January 1, 2002, and December 31, 2005, with claims for oxycodone ER, fentanyl transdermal system, any morphine ER formulation, or methadone. All claims for these agents were included regardless of the members' duration of coverage eligibility, diagnosis, days' supply or dose of medication. MassHealth members receiving methadone through a methadone maintenance program for the purposes of treating opioid addiction are not included in this data, since this therapy may be dispensed only by opioid treatment programs and is not billed for through the pharmacy online processing system.
Interventions
In 2002, the MassHealth DUR program performed a utilization data review and determined that a management strategy for LAOAs was warranted. Interventions were implemented via a multiple step process. Initially, PA restrictions on dose limits were implemented for oxycodone ER, fentanyl, morphine ER, and methadone. In order to determine high-dose criteria, dose per day was plotted against number of claims. The data fell into a bell shaped distribution with a long tail towards higher doses. Data in the long tail region of the graph were classified as "outliers" and were excluded from determination of the mean and standard deviation to avoid skewing the results. Doses identified as greater than 2 standard deviations above the mean were identified as high doses. This MassHealth utilization distribution analysis was repeated for all claims for each of the LAOAs for purposes of defining the PA high-dose requirement. Based on this analysis, the following were defined as dose limits; 240 mg per day (mg/day) of oxycodone ER, 200 micrograms per hour (µg/hr) of fentanyl, 360 mg/day of morphine ER, and 120 mg/day of methadone. These doses were specific to the observed utilization trends and not equipotent to each other. All high-dose LAOAs required a PA request for approval based on the defined high-dose criteria. All PAs for high-dose LAOAs submitted to MassHealth DUR are individually reviewed by clinical pharmacists accessing the member's pharmacy utilization database using a pharmacy claims program. All high-dose PA opioid requests require further documentation by prescriber for the (a) medical necessity for high dose (may require office note documentation or medical records); (b) complete pain management treatment plan; (c) previous trials of non-narcotic, narcotic, and nonpharmacological treatments (may require office notes or medical records); (d) signed and dated pain contract; (e) information about any history of early refill, lost, or stolen controlled substances; and (f) pain consult from pain specialist or specialized training in pain management that addresses the high dose. The clinical pharmacist would make a determination of PA approval or denial within 24 hours of request submission and fax the request back to the doctor's office with an outgoing message explaining the rationale for decision (Figure 1) .
In April 2004, MassHealth added PA requirement status for oxycodone ER and fentanyl transdermal system so that all "new starts" for these agents would require PA approval. The new starts were defined as a prescription for oxycodone ER or fentanyl transdermal system when there have been no paid claims for the medication in the last 90 days. Requests were also reviewed for trials of less costly alternatives. Morphine ER is considered the preferred less costly alternative on the MassHealth formulary. Members who were noted to have renal or hepatic dysfunction were able to bypass the morphine trial requirement due to the potential of medical risks associated with these conditions. Once a PA was approved, if the member continued to fill the medication in a manner that did not reclassify it as a new start and the dose did not escalate to one determined to be a high dose, there would be no further need for PA submission.
A multidisciplinary TCM workgroup team was also created to enable the implementation of clinical approval criteria and communication with MassHealth prescribers on PA requirements and restrictions. A team consisting of 2 physicians (internal medicine and anesthesiology with pain management specialty), 2 clinical pharmacists, and a behavioral health specialist pharmacist (addiction medicine) met every 2 weeks to discuss identified high-dose utilization regimen profiles. PA requests requiring phone interventions for clarification of PA requirements, treatment care plans, or specific restrictions, including alternative options for less costly alternative equally effective regimens, were facilitated by members of this multidisciplinary workgroup team. The development of the MassHealth PA clinical approval criteria and communication was guided by available evidence-based literature. 6, 12 Outcome Measures Primary Outcome Measures: Yearly changes in unique utilizers and the number of claims from the pre-initiative implementation period (2002) to the postinitiative implementation period (2005) were examined to describe the impact of requiring a PA for oxycodone ER, fentanyl transdermal system, morphine ER, and methadone. Average daily dose was also calculated to provide an illustration of the impact of dose limits that were implemented.
Secondary Outcome Measures:
A cost analysis was conducted to determine the impact, if any, of the multiple interventions. Total cost for each individual agent, total cumulative costs for all the long-acting agents, average cost per claim, and per-member-per-month (PMPM) metrics were also examined. 
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Statistical Analyses
The statistical significance of the change in utilizers and claims between years 2002 and 2005 were determined from the monthly averages within each respective year. The P values were calculated from these monthly averages by using the Student's t-test. A cost analysis on the cumulative impact of all implemented interventions was also performed and reported as change in total cost, as well as the impact on PMPM unit measure yearly costs for both overall and opioid utilizers. Inflation costs were calculated utilizing the CPI Inflation Calculator available at http://data.bls.gov/cgi-bin/cpicalc.pl.
■■ Results
Over the entire review period, the total pharmacy program enrollment remained relatively stable at approximately 700,000 lives annually. During the study period of 2002 to 2005, the total number of unique utilizer decreased by 17.8% (P < 0.0001), and the number of claims decreased by 4.1% (P < 0.0001; Table 1 ). There was an overall decrease in oxycodone ER and fentanyl transdermal system for both the number of unique utilizers and number of claims. Specifically, the number of unique utilizers and claims for oxycodone ER decreased by 6,201 (54.3%) and 29,944 (34.9%), respectively. For fentanyl transdermal system, unique utilizers decreased by 4,077 (50.6%), and the claims decreased by 10,578 (25.0%). Conversely, the utilization of morphine ER and methadone increased. Specifically, unique utilizers and claims for morphine ER increased by 3 Figure 2 . Morphine ER and methadone decreased by 20.8% and 19.9%, respectively. Conversely, there was a steady increase in fentanyl transdermal system doses for a total increase of 20.0% over the 4 years. Oxycodone ER also experienced an overall increase of 18.7% in the average daily dose, although the dose in 2005 was in fact lower than that documented in 2004. The average cost per claim was compared for LAOAs. Morphine ER and methadone average cost per claim decreased by 17% and 24%, respectively, whereas there was an increase for oxycodone ER and fentanyl by 21% and 32%, respectively ( Table 2 ). The 2005 overall cost of LAOAs decreased 8.0% compared with the overall cost in 2002.
The total amount paid for all LAOAs (reimbursement to the pharmacy for the prescription) initially showed an increase in the first 2 years, followed by a decrease in 2005 (Figure 3) . Most of the increase was a reflection of the amount paid for fentanyl transdermal system. Oxycodone ER showed a constant decrease, whereas morphine ER showed a steady increase, and methadone remained stable. The overall number of members in 2002 was 757,775, which decreased to 685,070 in 2005. The overall PMPM for all members decreased 6.3%, from $3.82 to $3.59, when costs were adjusted to 2005 dollars. Conversely, when applied to only opioid utilizers, the total number of members using opioids in 2002 was 24,153, which decreased to 19,855 in 2005. The PMPM for opioid utilizers increased 3.1%, from $120.04 to $123.75, when costs were adjusted to 2005 dollars. 
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defined high dose for morphine; however, a panel consensus has recently agreed that a reasonable definition is > 200 mg/ day (or equivalent). 6,10 The Massachusetts Medicaid program was able to develop a customized strategy using utilization trends to set parameters influenced by and applicable to the state Medicaid population.
The total number of MassHealth members that filled at least 1 claim for an LAOA decreased by 17.8% from 2002 to 2005. This result is in contrast to a previous report that the PA process had not exhibited a significant impact on the utilization of opioid medications. Our study has shown that certain policies are able to influence the overall trends in opioid utilization. Our study was able to have an effect on the overall practice of prescribing high-dose opioid medications. By implementing highdose definitions, monitoring PA utilization, and proactively intervening by reaching out to prescribers to address appropriate use of opioid treatment regimens, we were able to produce an impact on the overall utilization of LAOA medications.
■■ Discussion
There is a limited amount of published literature covering the impact of prescription opioid oversight and management despite the well-documented risks associated with the increasing utilization of this medication class. The Medicaid PA policies for many medication classes have been shown to decrease the use of targeted drugs by 15%-92%. [26] [27] [28] [29] However, previously published articles have reported that the PA policies in most states have had relatively minimal effect in decreasing the utilization of opioid medications. 31 Our study successfully demonstrated that a state Medicaid program initiative can result in a significant overall decrease in utilization, specifically for the targeted, more costly opioids. A number of management strategies were implemented during this initiative. These strategies included determining medical necessity, requiring step therapy through less costly alternatives, and implementing PA high-dose limits.
Defining a ceiling dose for opioids management can be difficult. The American Pain Society recognizes there is no 
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It is important to note that the higher average daily dose of oxycodone ER and fentanyl transdermal system observed during the analysis may be partially explained by the requirement of a morphine ER or methadone trial prior to approval of both of these agents. Since doses are increased to pain relief or response when possible, when members are approved for oxycodone ER or fentanyl transdermal system, their average daily doses are expected to have already been escalated to accommodate the required primary trial of morphine ER utilization. This will have the effect of increasing the doses of the requested oxycodone ER and fentanyl transdermal system regimens. Any changes in trends may have also been masked by the difficulty in dose conversion calculations. [33] [34] [35] When overall opioid costs were examined, there was a steady increase until 2004. After this point, there was a significant reversal of the trend toward lower cost. This coincided with a downward trend in cost noted for both oxycodone ER and fentanyl transdermal system. We have concluded that this trend is in direct relation to the new start PA policy for these medications. The introduction of generic formulations during this time period did not influence these results as indicated by the consistent average cost per claim noted in Table 2 .
Contrary to previous reports, this study shows that policy has the ability to affect the utilization of opioids. Furthermore, we implemented an initiative that was guided by clinical approval criteria set forth in the approach to appropriate pain management. This initiative was able to incorporate the likely need for dose increase due to inherent tolerance of this class of medications while properly balancing with the growing need to address potential misuse and abuse of opioid medications.
Limitations
When evaluating for potential limitations of our study, it is noted that a morphine equipotent ratio is used to determine or calculate the oral morphine equivalent doses. These ratios are not universally agreed upon, and there are differing ratios found in the literature. [33] [34] [35] [36] Another limitation could be the time frame between the implementation of changes and evaluation of outcomes when it comes to cost benefit. The overall cost of LAOAs decreased during the study period of 2002 to 2005, which correlated with an overall plan PMPM cost decrease of 6.3%. However, there was an increase (albeit smaller) of 3.1% PMPM increase in the opioid utilizer cohort. This could be explained by the fact that opioid utilizers at the second time point had demonstrated a need for more intense and more specific opiate selection for treatment. Specifically, chronic pain therapy typically requires increasing doses due to analgesic tolerance, and switching opiate therapy is a method of treating opiate tolerance.
■■ Conclusions
The importance of the initiative studied here has recently been highlighted by a call for changes in opioid prescribing practices in response to a perceived epidemic of prescription drug abuse. 37 When the PA process to monitor utilization was initially implemented, there were limited guidelines on the appropriate utilization of these agents. The American Society of Interventional Pain Physicians recently released updated guidelines for responsible opioid prescribing in chronic noncancer pain. 38 This updated guideline provides increasing evidencebased support for the interventions that we have described in this study. Our study demonstrated that a state Medicaid program initiative can be successfully implemented to address the need of increased monitoring and management of LAOAs.
